The comment “Value of hospital datasets of COVID-19 patients across different pandemic periods: challenges and opportunities” analyzed the information obtained from hospitalized patients regarding the severity of COVID-19 across different pandemic periods and SARS-cov-2 variants.
Incredibly, people close to an infected vaper using an e-cigarette in home or restaurant scenarios face a one percent increase of risk of contagion compared to the control case of a normal breathing (without vaping) inside closed spaces. This relative added risk becomes 5-17 percent for high intensity vaping and up to 260 percent for speaking for various periods and coughing.
CoEHAR researchers investigated for the first time the relationship between biochemically-verified smoking status and SARS-CoV-2 infection in a large population study. The study “The impact of laboratory-verified smoking on SARS-CoV-2 infection: Results from the Troina sero-epidemiological survey”, found that the prevalence of SARS-CoV-2 antibody positivity were reduced in smokers compared to former and never smokers (19.8% vs. 31%)
According to the researchers from CoEHAR, the Center of Excellence for the acceleration of Harm Reduction of the University of Catania, in partnership with the University of Pavia and the University of Milan “Statale”, the analysis of the international studies conducted on the humoral response to Covid-19 vaccines confirmed the negative impact of smoking on antibodies levels induced by vaccine and the rapid lowering of the vaccine-elicited IgG titres over six months
Nicotine is a protective shield against the insurgence of severe symptoms of COVID-19. This is what emerged with the new study by CoEHAR